Cetuximab-platinum chemotherapy is used for recurrent-metastatic head and neck squamous cell carcinoma (HNSCC), however a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation.
- Received March 22, 2016.
- Accepted March 23, 2016.
- Copyright ©2016, American Association for Cancer Research.